Skin Rash
Conditions
Keywords
skin rash, lapatinib, cetuximab, erlotinib, panitumumab
Brief summary
The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).
Detailed description
Epidermal growth factor (EGF) and its receptor, the EGFR, are known to be key drivers in cellular proliferation and survival. Malignant tumors result from uncontrolled cell proliferation. The use of drugs which target the EGF receptor has offered patients with non-small cell lung cancer, pancreatic cancer, head and neck cancer, and colorectal cancer additional targeted anti-cancer therapy in addition to their chemotherapeutic regimens. As a result of increased use of these EGFR inhibitors, adverse events have emerged involving the skin, hair, nails and eyes. While the EGFR inhibitors block the signal transduction that interfere with cellular proliferation and survival of cancerous cells, they also affect the normal EGF function in the skin (papulopustular rash), hair, and nails. In this study, we seek to histologically characterize the papulopustular rash in patients who have been treated with lapatinib and compare our findings with those associated with three other EGFRIs, cetuximab, erlotinib and panitumumab.
Interventions
PROCEDURESkin Biopsy of Skin Rash Secondary to EGFRI Use
Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
Sponsors
GlaxoSmithKline
Northwestern University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients treated with lapatinib who developed skin toxicities and were biopsied. * Patients treated with erlotinib, cetuximab, or panitumumab who have been biopsied for skin rash.
Exclusion criteria
* Patients who do not fit above criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | 6 months |
Countries
United States
Participant flow
Recruitment details
A total of 8 samples per patient/inhibitor were collected, with a total of 32 patient specimens analyzed for this study.
Participants by arm
| Arm | Count |
|---|---|
| Patients Treated With Lapatinib (L) Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash. | 8 |
| Patients Treated With Cetuximab (C) Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash. | 8 |
| Patients Treated With Panitumumab (P) Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash. | 8 |
| Patients Treated With Erlotinib (E) Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash. | 8 |
| Total | 32 |
Baseline characteristics
| Characteristic | Patients Treated With Lapatinib (L) | Patients Treated With Cetuximab (C) | Patients Treated With Panitumumab (P) | Patients Treated With Erlotinib (E) | Total |
|---|---|---|---|---|---|
| Age, Continuous | 55.7 years | 54.5 years | 65 years | 66.7 years | 60.35 years |
| Region of Enrollment United States | 8 participants | 8 participants | 8 participants | 8 participants | 32 participants |
| Sex: Female, Male Female | 7 Participants | 4 Participants | 5 Participants | 2 Participants | 18 Participants |
| Sex: Female, Male Male | 1 Participants | 4 Participants | 3 Participants | 6 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 8 |
| serious Total, serious adverse events | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 8 |
Outcome results
Primary
Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab.
Time frame: 6 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular concretions | 3 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal eosinophilic infiltrate | 2 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal neutrophilc infiltrate | 1 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine necrosis | 0 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal monocytic infiltrate | 1 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal neutrophilic infiltrate | 2 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal eosinophilic infiltrate | 0 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal monocytic infiltrate | 0 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine dyskeratosis | 0 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Acanthosis | 1 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Sebaceous infiltrate | 0 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular eosinophilic infiltrate | 2 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular monocytic infiltrate | 2 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal atrophy | 7 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine infiltrate | 0 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neurtrophilic infiltrate | 5 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular dyskeratosis | 4 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dysmaturation | 2 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Parakeratosis | 1 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dysmorphic follicle | 4 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neutrophilic pustule | 3 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dyskeratosis | 3 Total number of cases |
| Patients Treated With Lapatinib (L) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Ulceration | 1 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine necrosis | 2 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Ulceration | 1 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Parakeratosis | 2 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Acanthosis | 1 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal atrophy | 5 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dysmaturation | 3 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dyskeratosis | 3 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal neutrophilc infiltrate | 1 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal monocytic infiltrate | 0 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal eosinophilic infiltrate | 0 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal neutrophilic infiltrate | 0 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal monocytic infiltrate | 4 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal eosinophilic infiltrate | 2 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular concretions | 5 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neutrophilic pustule | 4 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dysmorphic follicle | 2 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular dyskeratosis | 3 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neurtrophilic infiltrate | 5 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular monocytic infiltrate | 2 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular eosinophilic infiltrate | 1 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine dyskeratosis | 1 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine infiltrate | 0 Total number of cases |
| Patients Treated With Cetuximab (C) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Sebaceous infiltrate | 1 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dyskeratosis | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dysmaturation | 1 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular monocytic infiltrate | 2 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine necrosis | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Acanthosis | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Ulceration | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular eosinophilic infiltrate | 1 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dysmorphic follicle | 2 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular concretions | 2 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal monocytic infiltrate | 2 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal eosinophilic infiltrate | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Sebaceous infiltrate | 1 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular dyskeratosis | 1 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal eosinophilic infiltrate | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Parakeratosis | 1 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal atrophy | 2 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine dyskeratosis | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal neutrophilic infiltrate | 2 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine infiltrate | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal neutrophilc infiltrate | 0 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neurtrophilic infiltrate | 3 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal monocytic infiltrate | 4 Total number of cases |
| Patients Treated With Panitumumab (P) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neutrophilic pustule | 3 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal monocytic infiltrate | 4 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal eosinophilic infiltrate | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dysmaturation | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine necrosis | 1 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neutrophilic pustule | 6 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Ulceration | 2 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dysmorphic follicle | 4 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal atrophy | 4 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular dyskeratosis | 1 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular neurtrophilic infiltrate | 7 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Acanthosis | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine infiltrate | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular monocytic infiltrate | 2 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular eosinophilic infiltrate | 1 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Parakeratosis | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal monocytic infiltrate | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal neutrophilc infiltrate | 1 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Sebaceous infiltrate | 3 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal eosinophilic infiltrate | 1 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Follicular concretions | 3 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Dermal neutrophilic infiltrate | 4 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Eccrine dyskeratosis | 0 Total number of cases |
| Patients Treated With Erlotinib (E) | Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. | Epidermal dyskeratosis | 0 Total number of cases |